CN
CNVVF.US ConvaTec Group Plc
- Market cap
- USD 6.15B
- P/E
- 53.6x
- P/B
- 4.30x
- ROE
- 14.9%
- Dividend yield
- 2.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CNVVF.US undervalued?
Graham numberThe Graham number of ConvaTec Group Plc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ConvaTec Group Plc fundamental analysis
No fundamental analysis for ConvaTec Group Plc yet.
ConvaTec Group Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ConvaTec Group Plc
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, ac…
Full company profileConvaTec Group Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ConvaTec Group Plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.55B | 1.85B | 1.75B | 1.83B | 1.89B | 2.04B | 2.07B | 2.14B | 2.29B | 2.49B | 4.86B |
| Gross Profit | 807M | 952M | 904M | 956M | 1.02B | 1.12B | 1.12B | 1.20B | 1.28B | 1.38B | 2.64B |
| Operating Income | 180M | 262M | 259M | 96.9M | 211M | 204M | 207M | 263M | 325M | 416M | 706M |
| EBITDA | 271M | 424M | 441M | 321M | 449M | 398M | 454M | 456M | 540M | 645M | 1.15B |
| Net Income | -186M | 158M | 222M | 9.80M | 113M | 118M | 62.9M | 130M | 191M | 179M | 213M |
| EPS | -0.10 | 0.08 | 0.11 | 0.00 | 0.06 | 0.06 | 0.03 | 0.06 | 0.09 | 0.09 | 0.11 |
| Balance Sheet | |||||||||||
| Total Assets | 3.51B | 3.80B | 3.66B | 3.61B | 3.77B | 3.67B | 3.59B | 3.71B | 3.52B | 3.79B | 3.78B |
| Total Liabilities | 2.27B | 2.28B | 2.04B | 2.05B | 2.10B | 1.98B | 1.98B | 2.02B | 1.83B | 2.27B | 2.35B |
| Shareholders' Equity | 1.25B | 1.52B | 1.62B | 1.56B | 1.67B | 1.69B | 1.61B | 1.69B | 1.69B | 1.52B | 1.43B |
| Cash & Short-term Investments | 267M | 291M | 318M | 386M | 565M | 463M | 144M | 98.3M | 64.7M | 75.1M | 98.9M |
| Total Debt | 1.78B | 1.82B | 1.64B | 1.57B | 1.55B | 1.44B | 1.30B | 1.31B | 1.20B | 1.52B | 1.74B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 68.6M | 321M | 336M | 402M | 400M | 306M | 282M | 367M | 396M | 480M | 284M |
| Capital Expenditure | 62.2M | 89.1M | 68.9M | 61.4M | 86.2M | 94.1M | 144M | 129M | 122M | 138M | 505M |
| Free Cash Flow | 6.41M | 232M | 267M | 340M | 313M | 212M | 138M | 238M | 274M | 342M | -221M |
| Ratios | |||||||||||
| ROE | -14.9% | 10.4% | 13.7% | 0.6% | 6.7% | 6.9% | 3.9% | 7.7% | 11.3% | 11.8% | 14.9% |
| ROA | -5.3% | 4.2% | 6.1% | 0.3% | 3.0% | 3.2% | 1.8% | 3.5% | 5.4% | 4.7% | 5.6% |
| Net Profit Margin | -12.0% | 8.5% | 12.7% | 0.5% | 5.9% | 5.8% | 3.0% | 6.1% | 8.3% | 7.2% | 4.4% |
| Debt to Equity | 1.42x | 1.20x | 1.02x | 1.01x | 0.93x | 0.85x | 0.81x | 0.78x | 0.71x | 1.00x | 1.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ConvaTec Group Plc dividends
- Dividend yield
- 2.33%
- Forward dividend
- 0.07 USD
- Payout ratio
- 80.0%
- Ex-dividend date
- Aug 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 143M | 0.07 | 80.0% |
| 2024 | USD 130M | 0.06 | 68.3% |
| 2023 | USD 113M | 0.06 | 87.0% |
| 2022 | USD 88.1M | 0.04 | 140.1% |
| 2021 | USD 85.8M | 0.04 | 73.0% |
| 2020 | USD 62.9M | 0.03 | 55.9% |
| 2019 | USD 79.9M | 0.04 | 815.3% |
| 2018 | USD 71.5M | 0.04 | 32.3% |
| 2017 | USD 27.6M | 0.01 | 17.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3013:2964 on Apr 10, 2023.
Who owns ConvaTec Group Plc
- Insiders 0.20%
- Institutions 88.00%
- Public & others 11.80%
- Shares outstanding 1.91B
- Free float 1.95B
ConvaTec Group Plc company profile
- Company name
- ConvaTec Group Plc
- Ticker
- CNVVF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10,000
- Fiscal year end
- December
- Address
- 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
- Phone
- 44 11 8952 8100
- Website
- convatecgroup.com
About ConvaTec Group Plc
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.
ConvaTec Group Plc management
10- Mr. Jonathan Peter MasonCEO & Director · born 1964
- Ms. Fiona Victoria RyderCFO & Director · born 1975
- Mr. Peter JarvisChief Operations Officer
- Mr. Dave UbachsChief Digital & Information Officer
- Mr. James Edward Spencer KertonEVP, General Counsel & Company Secretary · born 1980
- Ms. Emma RoseEVP & Chief People Officer
- Ms. Kjersti Grimsrud Biotechnology, M.Sc.President & COO of Infusion Care · born 1961
- Mr. David ShepherdChief Commercial Officer
- Ms. Evelyn Douglas J.D.EVP and Chief Strategy & Business Development Officer
- Mr. Bruno PinheiroPresident & COO of Ostomy Care